Nuevolution AB is a Sweden-based biopharmaceutical company working to develop future medicine for the treatment of cancer and inflammatory diseases. The Companyâ€™s business is conducted through its wholly owned subsidiary, Nuevolution A/S.

Employees

Sector

Pharmaceuticals

More about the company

Delayed Nasdaq Stockholm			5-day change	1st Jan Change
- ^SEK	-.--%		-0.31%	+90.59%

19-07-03	Amgen Inc. completed the acquisition of Nuevolution AB (OM:NUE) from Industrifonden, Skandinaviska Enskilda Banken AB (publ.) (OM:SEB A), Sunstone LSV Fund I K/S, SEB-Stiftelsen, Skandinaviska Enskilda Bankens Pensionsstiftelse, S-E-Bankens Utvecklingsstiftelse and others.	CI
19-05-22	Nuevolution AB Reports Earnings Results for the First Quarter Ended of March 2019	CI

Market Cap	1.6B 1.37B 1.28B 1.18B 2.21B 154B 2.25B 15.21B 5.93B 76.95B 6.02B 5.89B 255B	P/E 2017	-5.8x	P/E 2018	-7.98x
Enterprise Value	1.5B 1.28B 1.2B 1.1B 2.06B 143B 2.1B 14.18B 5.53B 71.75B 5.62B 5.5B 238B	EV / Sales 2017	62.2x	EV / Sales 2018	66.9x
Free-Float	90.97%	Yield 2017 *	-	Yield 2018	-

19-07-03	Amgen Inc. completed the acquisition of Nuevolution AB (OM:NUE) from Industrifonden, Skandinaviska Enskilda Banken AB (publ.) (OM:SEB A), Sunstone LSV Fund I K/S, SEB-Stiftelsen, Skandinaviska Enskilda Bankens Pensionsstiftelse, S-E-Bankens Utvecklingsstiftelse and others.	CI
19-05-22	Nuevolution AB Reports Earnings Results for the First Quarter Ended of March 2019	CI
19-05-20	Amgen Inc. made an offer to acquire Nuevolution AB (OM:NUE) from Industrifonden, Skandinaviska Enskilda Banken AB (publ.) (OM:SEB A), Sunstone LSV Fund I K/S, SEB-Stiftelsen, Skandinaviska Enskilda Bankens Pensionsstiftelse, S-E-Bankens Utvecklingsstiftelse and others for SEK 1.6 billion.	CI
19-05-09	Nuevolution's BET-BD1 Selective Inhibitor and Candidate Compound, NUE20798, Shows Positive Effect on Disease Scoring and Biomarker Levels in an Atopic Dermatitis Mouse Model	CI
19-04-04	Nuevolution AB Announces Audited Consolidated and Parent Earnings Results for the Year Ended December 31, 2018	CI
19-02-28	Nuevolution AB Publ Reports Earnings Results for the Fourth Quarter Ended December 31, 2018	CI
19-02-21	Nuevolution AB Announces First Animal Preclinical Data	CI
18-11-27	Nuevolution AB Announces Earnings Results for the Third Quarter and Nine Months Ended September 30, 2018	CI
18-10-11	Nuevolution to Present Data from its Discovery Program Directed at Targeting the Key Disease Inflammatory Signaling Molecule, Interleukin-17A (IL-17A)	CI
18-08-31	Nuevolution AB Announces Executive Changes	CI
18-08-22	Nuevolution AB Announces Consolidated and Parent Earnings Results for the Second Quarter and Six Months Ended June 30, 2018	CI
18-08-22	Nuevolution Discloses the Identity of Its Cytokine X Program Being Interleukin IL-17A	CI
18-07-18	Amgen Exercises Opt-In Right in First Program from Multiple Target Research Collaboration with Nuevolution	CI

19-04-17	Nuevolution publ : Svenska & English	PU
19-04-17	Nuevolution publ : Svenska & Engslish	PU
19-04-17	Nuevolution publ : AGM Proxy form UK	PU
19-04-08	Nuevolution publ : Corporate Governance Report 2018	PU
19-03-19	Nuevolution publ : EDISON MARCH 2019	PU

Nuevolution AB (publ) Stock

Stocks

NUE

SE0007730650

Pharmaceuticals

Valuation: Nuevolution AB (publ)

Latest news : Nuevolution AB (publ)

Press Releases: Nuevolution AB (publ)

News in other languages: Nuevolution AB (publ)

Biopharmaceuticals

Financials

Company Profile

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
NUEVOLUTION AB (PUBL)	-.--%	-0.31%	-	-	0
REGENERON PHARMACEUTICALS, INC.	-1.69%	+2.56%	+39.87%	+1.75%	82.54B
MODERNA, INC.	-23.55%	+109.46%	+395.80%	+31.19%	53.23B
CSL LIMITED	-1.72%	+23.37%	-25.49%	-36.90%	58.38B
SAMSUNG BIOLOGICS CO.,LTD.	+1.94%	+0.64%	+0.46%	+32.78%	52.24B
UCB	+0.05%	-0.55%	+11.63%	+170.68%	48.52B
BIOGEN INC.	-3.25%	+1.76%	+54.22%	-17.92%	31.67B
INCYTE CORPORATION	-0.97%	+5.56%	+47.59%	+98.66%	25.79B
INNOVENT BIOLOGICS, INC.	+1.48%	+9.49%	+3.42%	+229.70%	22.46B
SWEDISH ORPHAN BIOVITRUM AB	-0.90%	+2.85%	+62.35%	+125.73%	16.91B
Average	-0.81%	+15.28%	+65.54%	+70.63%	39.17B
Weighted average by Cap.	-1.04%	+20.07%	+70.29%	+48.27%

	2017	2018
Net sales	9.65M 8.27M 7.71M 7.08M 13.3M 924M 13.56M 91.49M 35.66M 463M 36.25M 35.46M 1.53B	10.97M 9.4M 8.77M 8.04M 15.11M 1.05B 15.41M 104M 40.54M 526M 41.2M 40.3M 1.74B
Net income	-123M -105M -97.86M -89.8M -169M -11.72B -172M -1.16B -453M -5.87B -460M -450M -19.45B	-99.72M -85.38M -79.66M -73.1M -137M -9.54B -140M -945M -368M -4.78B -374M -366M -15.83B
Net Debt	-111M -95.14M -88.77M -81.46M -153M -10.63B -156M -1.05B -411M -5.33B -417M -408M -17.64B	-108M -92.75M -86.54M -79.41M -149M -10.37B -152M -1.03B -400M -5.19B -407M -398M -17.2B